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Abstract
Synchronized diaphragmatic stimulation (SDS) is a novel extra-cardiac device-based therapy for symptomatic heart failure with
reduced ejection fraction. SDS provides imperceptible chronic stimulation of the diaphragm through a laparoscopically implanted system consisting of an implantable pulse generator and two sensing/stimulating leads afﬁxed to the inferior surface
of the diaphragm delivering imperceptible R-wave gaited pulses that alter intrathoracic pressure improving ventricular ﬁlling
and cardiac output. We describe, in a man with a history of myocardial infarctions resulting in heart failure and persistent New
York Heart Association Class III symptoms despite standard therapies, the successful implantation of SDS resulting in improved
quality of life, N-terminal pro brain natriuretic peptide, cardiac function, and exercise tolerance through 12 months of followup. Randomized trials are now required to validate these ﬁndings.
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Introduction
Synchronized diaphragmatic stimulation (SDS) is under investigation for patients with symptomatic heart failure and
reduced left ventricular ejection fraction (LVEF) who are not
candidates for cardiac resynchronization therapy due to degree of QRS prolongation or vascular access. Chronic stimulation of the diaphragm is provided by a system consisting of an
implantable pulse generator (IPG) and two sensing/stimulating leads afﬁxed to the diaphragm. The IPG delivers imperceptible R-wave gaited pulses (Figure 1) that alter intrathoracic pressures thereby improving ventricular ﬁlling and
cardiac output. A system for delivering SDS (VisCardia Inc.,
Portland, OR) that allows minimally invasive implantation
has been studied in a pilot study (NCT0348470), in which this
patient participated.1,2 This study was approved by the Ethics

Committee of Tbilisi Heart and Vascular Clinic 18/20
Ljublijana Str., Tbilisi 0159, Georgia.

Case report
A 58-year-old man with past history of ischaemic cardiomyopathy and LVEF of 30% presented with worsening dyspnoea
on exertion. On examination, his heart rate was 80 bpm,
blood pressure 134/79 mmHg, a mild audible diastolic
murmur but no abnormal heart sounds or jugular venous
distention. His lungs were clear with good air movement
bilaterally and no rales. A 12-lead ECG showed sinus rhythm,
normal QRS duration but poor R-wave progression. His
medications included torsemide, spironolactone, carvedilol,
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Figure 1 SDS stimulation and localized diaphragmatic acceleration. (A) Simultaneous recording of ECG and acceleration from probes attached to the
diaphragm. SDS leads to short biphasic diaphragm movements superimposed onto the respiratory cycle. (B) Single beat recording of ECG and acceleration. SDS produces a caudal movement of the diaphragm (blue arrows) that is followed by a cranial rebound (green arrows). ECG, electrocardiogram; SDS, synchronized diaphragmatic stimulation.

a combination of perindopril, amlodipine and indapamide
(thiazide), as well as aspirin and atorvastatin.
The patient had myocardial infarctions 18 and 20 years prior
to enrolment involving the anterior wall of the left ventricle.
He was found to be hypertensive 11 years prior to enrolment
and his medical regimen was adjusted. Six years prior to enrolment, he underwent coronary artery bypass grafting (left internal mammary to the left anterior descending artery;
saphenous vein graft to the posterior descending artery). A
transthoracic echocardiogram shortly before enrolment
showed moderate left ventricular hypertrophy and dilatation,
moderate aortic regurgitation, mild mitral regurgitation, and
an LVEF of 30%. Despite guideline directed medical therapy
for over 1 year, the patient remained symptomatic exhibiting
on-going dyspnoea with moderate exertion and fatigue
consistent with New York Heart Association (NYHA) Class III
symptoms.
Results of the patient’s laboratory tests were as follows:
serum creatinine, 1.38 mg/dL (normal, <1.2 mg/dL);
haemoglobin, 153 g/L (normal, 126–174 g/L); and NT-proBNP,
1779 pg/mL (normal, <125 pg/mL). Spirometry revealed mild
restriction "(forced vital capacity 3.25 L, forced expiratory
volume in 1 s 2.71 L, forced vital capacity ratio 83%). To establish exercise tolerance, a 6 min walk test was performed
(start/end heart rate 80/99 bpm, start/end SpO2 97/91%, distance 302 m). The 6 min walk test was consistent with NYHA
functional class III.
Based on the patient’s history of heart failure with reduced
LVEF (HFrEF) and declining exercise tolerance and quality of
life (QOL), despite maximally tolerated guideline directed

medical therapy, the patient was invited to participate in a
non-randomized, pilot study investigating the technical feasibility of SDS implantation. The patient consented to the study
as previous therapy including coronary artery bypass grafting
and current GDMT therapy had not adequately controlled his
symptoms, and he did not qualify for alternative therapies
including cardiac resynchronization therapy or valve
interventions.
The SDS system was implanted via minimally invasive abdominal access, Figure 2A. A small midline incision (location
a) was made to place the trocar and laparoscope. The abdomen was insufﬂated to allow adequate visualization of the diaphragm. Another small incision was made laterally (location
b) to place another trocar through which the sensing/stimulating leads were inserted and attached to the left and right
hemispheres of the diaphragm (locations c). A laparoscopic
view of the sensing/stimulating leads is provided in panel B.
A subcutaneous pocket was created for the IPG (panel A, location d) and the leads tunnelled to connect to the IPG. Sensing thresholds were tested for adequate performance, and
the diaphragmatic capture threshold was determined. The
abdomen was desufﬂated, and all incisions were closed.
Chest X-rays were taken to document lead placement (panels
C and D). Prior to discharge on post-operative Day 2, device
performance was conﬁrmed and the therapy activated to
deliver SDS therapy at an asymptomatic threshold.
The patient was evaluated at 3, 6, and 12 months
post-discharge for QOL using SF-36 (Short Form Health Survey), spirometry, exercise tolerance, and echocardiography.
Figure 3 illustrates changes in 6 min walk distance (panel
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DOI: 10.1002/ehf2.13882

Synchronized diaphragmatic stimulation

1679

Figure 2 Minimally invasive SDS placement. (A) Laparoscopic access points: a, midline incision for trocar and camera; b, lateral incision for trocar and
leads; c, location of leads placed on the diaphragm (red dashed line); d, location of IPG pocket. (B) Laparoscopic view of bilateral diaphragmatic lead
locations. (C) Posteroanterior radiographic view of leads. (D) Left lateral radiographic view of leads.

Figure 3 Chronic impact of SDS. Change over 12 months. (A) 6 MWTD, 6 min walk test distance (metres). (B) NT-proBNP (pg/mL). 6MWTD, 6 min walk
test distance; NT-proBNP, N-terminal pro brain natriuretic peptide.
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A, pre-implant = 302 to 12 month = 392 m) and NT-proBNP
(panel B, screen = 1779 to 12 month = 736 pg/mL) over
time. Substantial improvements occurred in LVEF (pre-implant = 28% vs. 12 month = 51%), and SF-36 QOL measures
(role physical, pre-implant = 0 vs. 12 month = 25; role
emotional, pre-implant = 0 vs. 12 month = 67) while no
deterioration was seen in respiratory function (Table 1 and
Figure 4).

Discussion
Heart failure is often associated with debilitating symptoms,
recurrent hospitalizations, and a poor prognosis. Although innovations in pharmacological and device therapy have improved the outlook for many patients with HFrEF, there is still
a need for further treatments that are effective for improving
symptoms and/or prognosis, safe, minimally invasive or noninvasive, non-burdensome, and affordable. Despite appropriate pharmacological therapy,3 this patient had worsening
QOL, decreasing ability to perform daily activities and

frequent acute heart failure episodes. Following placement
of the SDS system, the patient experienced improved clinical
status and improved LVEF.
The mechanism of action of the SDS system on improved
cardiovascular symptoms is unknown, but one hypothesis is
the impact of diaphragmatic pacing on intrathoracic
pressures translating to changes in ventricular pre-load,
after-load, and pericardial restraint. Electrical stimulation of
the diaphragm causes a contraction that transiently modulates intrathoracic pressure in a biphasic manner (Figure 1),
which is imperceptible by the patient.4 Changes in intrathoracic pressure due to diaphragmatic movement are known
to affect haemodynamics and cardiac loading, such as during
respiration. Inspiration reduces intrathoracic pressure while
increasing intra-abdominal pressure resulting in increased
systemic venous return and pulmonary venous capacitance.
During inspiration, right atrial and right ventricular volume increase while left atrial and left ventricular volume decrease.
During expiration, increased intrathoracic pressure results in
the reduced right-sided volumes and increased left-sided volumes. More recently, there has been increased interest in the
impact of intrathoracic pressure changes on pericardial

Table 1 Change over 12 months

Pre-implant
3 months
6 months
12 months

HR
(bpm)

SBP
(mmHg)

DBP
(mmHg)

6MWTD
(m)

NT-proBNP
(pg/mL)

EF
(%)

ESV
(mL)

FEV1
(L)

FVC
(L)

SF-36 role,
physical

SF-36 role,
emotional

82
78
75
79

129
106
138
126

69
68
69
67

302
330
347
392

1779
1190
910
736

28
43
39
51

162
102
115
101

2.7
2.5
2.7
2.7

3.3
3.0
3.2
3.3

0
25
25
25

0
67
67
67

6MWTD, 6 min walk test distance; DBP, diastolic blood pressure; EF, left ventricular ejection fraction; ESV, left ventricular end-systolic
volume; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HR, heart rate; SBP, systolic blood pressure; SF-36, Short
Form Health Survey.

Figure 4 Percent change from pre-implant to 12 months. Percent change from pre-implant value. 6MWT Distance, 6 min walk test distance; DBP, diastolic blood pressure; HR, heart rate; LV EF, left ventricular ejection fraction; LV ESV, left ventricular end-systolic volume; SBP, systolic blood pressure.
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restraint.5 Stimulation of the diaphragm leads to reduced
pericardial restraint and a reduction in ventricular wall stress,
which could improve cardiac ﬁlling conditions and systolic
performance.
Several research groups have independently demonstrated
that even short transient, non-respiratory intrathoracic pressure changes such as due to hiccoughs, controlled phrenic
nerve stimulation or respirator bursts, affects cardiac and
large vessel pressures and ﬂows.6–8 Using a temporary pacing
lead attached to the diaphragm, Roos et al.9 demonstrated
the ability to stimulate, asymptomatically, the diaphragm in
35 patients leading to reproducible acute improvements to
cardiac function. The effects of chronic SDS were investigated
in patients after coronary artery bypass grafting with a pacing
lead attached to the diaphragm.10 Patients (n = 24) were randomized in a crossover trial with 3-week treatment periods.
Symptoms, exercise tolerance, and echocardiographic
parameters were assessed at the end of each period. With
timing-optimized SDS, LVEF increased and NYHA class and
exercise performance improved. Some patients were
followed for 1 year (n = 17),11 and the improvements in LVEF
were sustained in those without comorbid respiratory
disease (e.g. COPD).

Synchronized diaphragmatic stimulation, a new
device-based intervention for symptomatic HFrEF, appears
promising when guideline directed medical therapy does
not adequately control symptoms. This case report highlights
the clinical response to SDS after 1 year of follow-up in one of
the ﬁrst patients to receive this therapy. Randomized trials
are now required to validate these ﬁndings.
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